The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Multi-target approach for natural products in inflammation
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs
VANE, J. R. (1971) · Nature New Biology · doi:10.1038/newbio231232a0 · Cited by 8,605
Origin and physiological roles of inflammation
Medzhitov, R. (2008) · Nature · doi:10.1038/nature07201 · Cited by 6,618
Natural products in drug discovery
Harvey, A. L. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.07.004 · Cited by 1,832
Inhibition of NF-κB by Sodium Salicylate and Aspirin
Kopp, E., & Ghosh, S. (1994) · Science · doi:10.1126/science.8052854 · Cited by 1,753
Mitchell, J. A., Akarasereenont, P., Thiemermann, C., Flower, R. J., & Vane, J. R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11693 · Cited by 1,659
Singh, B. N., Shankar, S., & Srivastava, R. K. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.07.093 · Cited by 1,602
Designed Multiple Ligands. An Emerging Drug Discovery Paradigm
Morphy, R., & Rankovic, Z. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm058225d · Cited by 1,209
Multi-target therapeutics: when the whole is greater than the sum of the parts
Zimmermann, G. R., Lehár, J., & Keith, C. T. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.11.008 · Cited by 1,105
McGettigan, P., & Henry, D. (2006) · JAMA · doi:10.1001/jama.296.13.jrv60011 · Cited by 1,096
BALOGUN, E., HOQUE, M., GONG, P., KILLEEN, E., GREEN, C. J., FORESTI, R., ALAM, J., & MOTTERLINI, R. (2003) · Biochemical Journal · doi:10.1042/bj20021619 · Cited by 1,036
Research works printed but not linked: 9
- Jund, 2012, Clinical efficacy of a dry extract of five herbal drugs in acute viral rhinosinusitis, Rhinology, 50, 417, 10.4193/Rhino.12.015 · doi:10.4193/rhino.12.015
- Cheng, 2001, Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions, Anticancer Res., 21, 2895
- Sharma, 2001, Effects of dietary curcumin on glutathione S-transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa: relationship with drug levels, Clin. Cancer Res., 7, 1452
- Brune, 1977, Biodistribution of salicylates: a clue to the understanding of some effects and side effects, Agents Actions Suppl., 2, 163
- Fang, 2003, Tea polyphenol (−)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines, Cancer Res., 63, 7563
- Naasani, 2003, Blocking telomerase by dietary polyphenols is a major mechanism for limiting the growth of human cancer cells in vitro and in vivo, Cancer Res., 63, 824
- Holmes-McNary, 2000, Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase, Cancer Res., 60, 3477
- Hope, 2008, Low concentrations of resveratrol inhibit Wnt signal throughput in colon-derived cells: implications for colon cancer prevention, Mol. Nutr. Food Res., 52, 52
- Gulati, 2006, The antiproliferative effect of quercetin in cancer cells is mediated via inhibition of the PI3K–Akt/PKB pathway, Anticancer Res., 26, 1177
Cited by
Counting on natural products for drug design
Rodrigues, T., Reker, D., Schneider, P., & Schneider, G. (2016) · Nature Chemistry · doi:10.1038/nchem.2479 · Cited by 1,250
Curcumin, Inflammation, and Chronic Diseases: How Are They Linked?
He, Y., Yue, Y., Zheng, X., Zhang, K., Chen, S., & Du, Z. (2015) · Molecules · doi:10.3390/molecules20059183 · Cited by 608
Talevi, A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00205 · Cited by 381
Molecular Hybridization as a Tool for Designing Multitarget Drug Candidates for Complex Diseases
Ivasiv, V., Albertini, C., Gonçalves, A. E., Rossi, M., & Bolognesi, M. L. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190619115735 · Cited by 375
Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms
Zhou, J., Jiang, X., He, S., Jiang, H., Feng, F., Liu, W., Qu, W., & Sun, H. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00017 · Cited by 281
Anti-inflammatory activity of natural stilbenoids: A review
Dvorakova, M., & Landa, P. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.08.002 · Cited by 268
Markers and Biomarkers of Endothelium: When Something Is Rotten in the State
Goncharov, N. V., Nadeev, A. D., Jenkins, R. O., & Avdonin, P. V. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/9759735 · Cited by 190
“Many nutraceuticals have multiple molecular and functional targets in humans and animals, and at least two consequences follow from this fact: (1) experimental animal and in vitro studies can hardly be overestimated; (2) studies of nutraceuticals should be based on the multitarget drug approach, according to which foc…”
A Review on Fucoidan Structure, Extraction Techniques, and Its Role as an Immunomodulatory Agent
Jayawardena, T. U., Nagahawatta, D. P., Fernando, I. P. S., Kim, Y.-T., Kim, J.-S., Kim, W.-S., Lee, J. S., & Jeon, Y.-J. (2022) · Marine Drugs · doi:10.3390/md20120755 · Cited by 149
Combination therapeutics in complex diseases
He, B., Lu, C., Zheng, G., He, X., Wang, M., Chen, G., Zhang, G., & Lu, A. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12930 · Cited by 112
“However, additional kinases with structural similarities will be inhibited, potentially leading to additional toxicity because cumulative target and off-target inhibition has a broader, and perhaps less predictable, effect on cellular functions [24, 25].”
Background
Metadata
- Authors
- Koeberle, A., & Werz, O.
- Venue
- Drug Discovery Today
- Publisher
- Elsevier BV
- Published
- 2014-12
- Volume
- 19
- Issue
- 12
- Pages
- 1871-1882
- ISSN
- 1359-6446 (ISSN-L)
- OpenAlex
- W1984417882
- Cited by
- 317
- References
- 101
- FWCI
- 24.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.